A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Lee J, Park S, Jung HA, Lee SH, Seo S, Kim SB, Kim JW, Lee KW, Kang EJ, Kim JW, Choi YJ, Shim BY, An HJ, Park LC, Shin SH, Kim JJ, Oh SY, Kim MK, Ahn MJ.
Lee J, et al. Among authors: park s, park lc.
Cancer. 2023 Oct 1;129(19):2966-2974. doi: 10.1002/cncr.34892. Epub 2023 May 28.
Cancer. 2023.
PMID: 37246414
Clinical Trial.